Cervical Cancer Pipeline Review H2 2015

1. Cervical Cancer - Pipeline Review, H2 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 30-Oct-2015 No. of Pages:348 Single User License: US $2000 Browse more Reports on Diseases & treatment at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

2. Cervical Cancer - Pipeline Review, H2 2015 This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

3. Cervical Cancer - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research: 3SBio Inc., Admedus Ltd, Advaxis, Inc., AnGes MG, Inc., Antigen Express, Inc., Arbor Vita Corporation, ArQule, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Azaya Therapeutics, Inc., BIND Therapeutics, Inc., Cancer Research Technology Limited, Cellceutix Corporation, Chong Kun Dang Pharmaceutical Corp., Critical Outcome Technologies Inc., CZ BioMed Corp, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Limited, EirGenix Inc., Eisai Co., Ltd., Epirus Biopharmaceuticals, Inc., EyeGene, Inc., F. Hoffmann-La Roche Ltd., Formune S.L., Genexine, Inc., Genmab A/S, GenorBioPharma Co., Ltd., Genticel S.A., GlaxoSmithKline Plc, Hetero Drugs Limited, Immunovaccine, Inc., Indian Immunologicals Limited, ISA Pharmaceuticals B.V., Karyopharm Therapeutics, Inc., Kite Pharma, Inc., LondonPharma Ltd, Mabion SA, MedImmune, LLC, MEI Pharma, Inc., Mycenax Biotech Inc., Nanotherapeutics, Inc., Nektar Therapeutics, Novartis AG, Oncobiologics, Inc., Oryx GmbH & Co. KG, Otsuka Holdings Co., Ltd., Redbiotec AG, Rexahn Pharmaceuticals, Inc., Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., ShanthaBiotechnics Limited, Sirnaomics, Inc., Sun Pharma Advanced Research Company Ltd., Taiho Pharmaceutical Co., Ltd., Theravectys SA, Vaccibody AS, VLPbio, Zeria Pharmaceutical Co., Ltd. and ZydusCadila Healthcare Limited ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

4. Cervical Cancer - Pipeline Review, H2 2015 Drugs Profile Discussed in this Research: (tegafur + gimeracil + oteracil), AEH-10p, aminolevulinic acid hydrochloride, Antisense Oligonucleotides for Cervical Cancer, Aptamer to Target HPV E7 Protein for Cervical Cancer, ARQ-092, artemether, AV-203, AVC-7, AZD-1775, AZD-5363, bevacizumab, bevacizumab biosimilar, BLI-1004, buparlisib hydrochloride, Cell Therapy for Cervical Carcinoma, Cell Therapy for HPV Associated Cancers, Cell Therapy for HPV-Associated Cancer and Cervical Cancer, Cell Therapy to Target HPV-16 E6 Protein for Cancer, Cell Therapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer, CerviVax, Cervlysis, CIGB-300, CKD-12201, COTI-2, crocetin, dianhydrogalactitol, docetaxel, docetaxel, DPX-E7, durvalumab + tremelimumab, E-7046, EDA-HPVE7, EG-HPV, etirinotecanpegol, everolimus, GSK-2849330, GX-188E, human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar, HuMax-TF-ADC, INO-3112, ISA-101, KM-3174, Lovaxin S, mapatumumab, ME-344, nimotuzumab, NP-001, NTCP-02, OPB-111001, OTAC-DCtag, paclitaxel albumin free, patritumab, pazopanib hydrochloride, Peptides to Inhibit Bcl-x and MCL-1 for Oncology, ProCervix, RA-190, RBT-201, RX-3117, S-009131, selinexor, Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology, SSS-08, STP-909, TA-CIN, TAS-114, Tenacinol, Triapine, TT-12, Vaccine for Cervical Cancer, vaccine for cervical cancer, Vaccine for Cervical Cancer and Genital Warts, Vaccine for Cervical Cancer, Head And Neck Cancer, Vaccine for HPV Associated Cancers, Vaccine for Human papillomavirus Associated Cervical Cancer, Vaccine to Target HIG2, VEGFR-1 and VEGFR-2 for Ovarian Cancer and Cervical Cancer, Vaccine to Target HPV E7 Protein for Cervical Cancer, Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer, VB-1016, Vicoryx, Vvax-001 and Z-100 ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

5. Cervical Cancer - Pipeline Review, H2 2015 Scope For Cervical Cancer - Pipeline Review, H2 2015 • The report provides a snapshot of the global therapeutic landscape of Cervical Cancer • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Cervical Cancer and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects • Coverage of the Cervical Cancer pipeline on the basis of target, MoA, route of administration and molecule type ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

6. Cervical Cancer - Pipeline Review, H2 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Cervical Cancer • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Cervical Cancer pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

7. Cervical Cancer - Pipeline Review, H2 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441